FDA Approves Inluriyo, First Oral Combination Pill for Common Breast Cancer Mutation
The FDA approved Inluriyo, also known as imlunestrant, as an oral combination pill for a common breast cancer mutation in September 2026. The approval gives patients a new treatment option that does not require intravenous administration. Healthline reported the approval as one of several significant drug decisions made by the agency this month.
The U.S. Food and Drug Administration approved Inluriyo, the brand name for imlunestrant, as an oral combination treatment for a common breast cancer mutation in September 2026.
The approval gives patients a pill-based option for a type of breast cancer that has traditionally required intravenous treatments. Oral therapies can make treatment more manageable for patients, reducing the need for clinic visits and IV administration.
Inluriyo targets a specific mutation that is present in a significant portion of breast cancer cases. The drug works in combination with another agent to block the cancer's ability to grow.
Healthline reported the approval as part of a busy month for the FDA, which also cleared Rasonque for metastatic pancreatic cancer and updated COVID-19 vaccines for the 2026-2027 season.
Clinical trial data submitted to the FDA showed that Inluriyo reduced the risk of disease progression compared to standard treatments. The agency reviewed the data and determined the benefits outweighed the risks for the indicated patient population.
Breast cancer remains one of the most common cancers among women in the United States. Advances in targeted therapies have improved survival rates significantly over the past two decades, and Inluriyo represents another step in that direction.
Patients and oncologists are expected to discuss the new option during treatment planning conversations. The drug's manufacturer has not yet announced pricing details.
